Disparities Exist in Young Patients with Colorectal and Gastric Cancers

Video

The incidence of colorectal and gastric cancers has risen for younger patients, and many of them share ethnic and socioeconomic disparities as well.

As the incidence of colorectal and gastric cancers in younger patients has risen in recent years, researchers have found this population to have other factors in common — most notably ethnic and socioeconomic disparities.

Dr. Amir Khan and his team analyzed data from the California Cancer Registry spanning from 2000 to 2012 to find information on the different age groups of patients who have received colorectal and gastric cancer diagnoses. They found an increased incidence of the disease in patients aged 18-40, and that these younger patients were more likely to be uninsured, of low socioeconomic status or of Hispanic descent.

During the annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Khan, a fellow in surgical oncology at City of Hope National Medical Center in Duarte, California, met with CURE® to discuss the results of his team’s study and the data their findings have uncovered.

Transcription:

We found that the youngest age group, 18-40, (that there were) ethnic and socioeconomic disparities. Hispanic ethnicity was much more common in the younger population. In the group that was aged 65-90 maybe about 20% of gastric cancers were among Hispanics as opposed to the 18-40 group (where) 50% of patients were Hispanic.

We also found that younger patients were more likely to be uninsured and of low socioeconomic status. We found that these patients may present with later stage disease — stage 3 and stage 4 — and they had certain histopathologic features that suggested a more aggressive disease process. They had more poorly differentiated tumors, (and) in terms of gastric cancer they had diffuse type pathology and poorly differentiated tumors as well.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content